Skip to main content
. 2022 Jun 30;8(8):1169–1176. doi: 10.1001/jamaoncol.2022.2253

Figure 3. Best Percentage of Change in Target Lesions.

Figure 3.

PLD indicates pegylated liposomal doxorubicin. The horizontal dashed lines represent the criteria of progrssive disease or partial response according to Response Evaluation Criteria in Solid Tumours, version 1.1.